N6-methyladenosine (m6A) methyltransferase KIAA1429 accelerates the gefitinib resistance of non-small-cell lung cancer

Jun Tang¹, Tianci Han²,³, Wei Tong²,³, Jian Zhao²,³ and Wei Wang²,³

Abstract
N6-methyladenosine (m6A) modification has been convincingly identified to be a critical regulator in human cancer. However, the contribution of m6A to NSCLC gefitinib resistance is still largely unknown. Here, we screened and identified that m6A methyltransferase KIAA1429 was highly expressed in gefitinib-resistant NSCLC cells (PC9-GR), tissues, and closely related to unfavorable survival. Functionally, KIAA1429 accelerated the gefitinib resistance of NSCLC in vitro. Depletion of KIAA1429 repressed the tumor growth of PC9-GR cells in vivo. Mechanistically, KIAA1429 enhanced the mRNA stability of HOXA1 through targeting its 3′-untranslated regions (3′-UTR). Overall, our findings indicate that KIAA1429 plays essential oncogenic roles in NSCLC gefitinib resistance, which may provide a feasible therapeutic target for NSCLC.

Introduction
Non-small-cell lung cancer (NSCLC) acts as the major subtype of lung cancer approximately 85%¹,². NSCLC is the most common malignancy and could give rise to tens of millions of death cases worldwide³. The main reason for this phenomenon is that chemotherapy drugs and targeted therapies lose their efficacy in clinical therapeutics⁴. Among these targeted therapy drugs, epidermal growth factor receptor tyrosine (EGFR) kinase inhibitors function as the first-line agent for advanced NSCLC patients harboring EGFR mutation, including gefitinib and erlotinib⁵. One of the drawbacks to note is that the chemotherapy resistance of gefitinib in NSCLC causes great therapeutic impedance⁶. Therefore, it is urgent to identify the oncogenic mechanism origin of gefitinib resistance in NSCLC.

N6-methyladenosine (m6A) is a reversible and dynamic process regulated by methyltransferases (writers), demethylases (erasers), and effector proteins (readers)⁷–¹⁰. Increasing evidence has indicated the roles of m6A key enzyme in human cancers. For example, m6A methyltransferase METTL14 is overexpressed in pancreatic cancer cells, which promotes the proliferation and migration via directly targeting PERP mRNA in an m6A-dependent manner¹¹. Methyltransferase-like 3 (METTL3), METTL14, and Wilms tumor 1-associating protein (WTAP) construct a highly conserved multi-subunit methylase complex to mediate the conversion of adenosine to m6A. However, KIAA1429 is a subtype of m6A methyltransferase, which is well-known to all. In human cancer, KIAA1429 is found to be an oncogene. For example, KIAA1429 was upregulated in gastric cancer cells and tissues, which promotes the proliferation of gastric cancer cells. KIAA1429 regulates the c-Jun mRNA stability in an m6A-independent manner¹². Therefore, these findings suggest that KIAA1429 may regulate the human tumorigenesis.

m6A methyltransferase KIAA1429, also known as VIRMA (vir-like m6A methyltransferase-associated...
protein), is a novel m⁶A methyltransferase complex component. In the present study, we aim to address the key regulation regarding the expression and mechanism of KIAA1429 in NSCLC gefitinib resistance. Incipiently, KIAA1429 was significantly upregulated in the NSCLC tissue samples. Thus, we carried out a series of assays to identify the functions of KIAA1429 in NSCLC tumorigenesis.

**Results**

**m⁶A methyltransferase KIAA1429 was upregulated in lung cancer specimens**

In the gefitinib-resistant NSCLC cell (PC9-GR), several candidate m⁶A regulators were detected as compared to the parental sensitive cells. Data illustrated that m⁶A methyltransferase KIAA1429 was remarkably highly expressed in the PC9-GR cells (Fig. 1A). Moreover, in several NSCLC cell lines (H1299, A549, PC9, and PC9-GR), RT-qPCR showed that KIAA1429 mRNA was upregulated in the gefitinib-resistant NSCLC cell (PC9-GR) (Fig. 1B). In the NSCLC patients’ samples, KIAA1429 was significantly overexpressed as compared to normal tissue samples (Fig. 1C). The data on TCGA database (http://gepia.cancer-pku.cn/) showed that the patients with high KIAA1429 expression were tagged by lower survival percent (Fig. 1D). In addition to this, the survival analysis in the clinical cohort showed that the higher KIAA1429 expression was closely correlated with the lower survival of NSCLC patients (Fig. 1E). In conclusion, these findings implied that m⁶A methyltransferase KIAA1429 was upregulated in gefitinib-resistant NSCLC cells and closely correlated with the lower survival of NSCLC patients.

**KIAA1429 promoted the proliferation and gefitinib resistance of NSCLC cells**

In the gefitinib-resistant NSCLC cells (PC9-GR), the silencing and overexpression of KIAA1429 were constructed using short-hairpin RNA (shRNA) and overexpression plasmids. RT-qPCR demonstrated that KIAA1429 expression was remarkably upregulated in PC9-GR cells (Fig. 2A). Western blot analysis found that KIAA1429 protein was significantly silenced or upregulated in the plasmid transfection (Fig. 2B). Wound-healing
analysis found that KIAA1429 knockdown repressed the migrative ability and KIAA1429 overexpression accelerated the migrative ability (Fig. 2C). Gefitinib resistant analysis demonstrated that KIAA1429 knockdown reduced the IC50 value (inhibitory concentration 50) of PC9-GR cells, and KIAA1429 overexpression enhanced the IC50 value of PC9-GR cells (Fig. 2D). In conclusion, our findings suggested that KIAA1429 promoted the proliferation and gefitinib-resistant NSCLC cells.

**MeRIP-Seq revealed the m6A profile in gefitinib-resistant NSCLC cells**

Recent research illustrated the increasing role of m6A in human cancer; thus, the present study focused on the potential regulation of KIAA1429 on NSCLC gefitinib resistance. m6A quantitative analysis was carried out, showing higher m6A enrichment in the gefitinib-resistant cells (PC9-GR) (Fig. 3A). To discover the m6A profile in the gefitinib-resistant NSCLC cells, MeRIP-Seq was performed in PC9-GR and PC9 cells. The motif of KIAA1429 was identified (AUGGACU) (Fig. 3B). Metagene profile of m6A distribution across the transcriptome was detected by this MeRIP-Seq (Fig. 3C). Moreover, KIAA1429 knockdown repressed the m6A level in PC9-GR cells, while KIAA1429 overexpression upregulated the m6A level (Fig. 3D). In summary, these findings suggested that MeRIP-Seq revealed the m6A profile in gefitinib-resistant NSCLC cells.

**KIAA1429 enhanced the stability of HOXA1 mRNA**

Based on the MeRIP-Seq, we found that HOXA1 functioned as one of the targets of KIAA1429. Integrative
genomics viewer (IGV) tool showed that there was a remarkable m^6^A peak in the 3′-UTR of HOXA1 mRNA (Fig. 4A). In the PC9-GR cells, the HOXA1 mRNA expression was detected using qPCR, suggesting that HOXA1 mRNA level was statistically decreased upon KIAA1429 knockdown (Fig. 4B). Then, we performed RNA-binding protein immunoprecipitation assay (RIP) and data demonstrated that the KIAA1429 antibody could effectively combine with the HOXA1 mRNA, illustrating the interaction within KIAA1429 and m^6^A-modified HOXA1 mRNA (Fig. 4C). To further demonstrate the role of KIAA1429 on HOXA1 mRNA stability, MeRIP-qPCR with specific primers revealed that m^6^A modification level was reduced upon KIAA1429 knockdown (Fig. 4D). Interestingly, we also observed the HOXA1 mRNA stability decreasing upon KIAA1429 knockdown (Fig. 4E). Taken together, HOXA1 acted as a downstream target of KIAA1429, and KIAA1429 enhanced the stability of HOXA1 mRNA.

KIAA1429/HOXA1 axis promoted the proliferation and gefitinib resistance of NSCLC cells

Based on the TCGA database (http://gepia.cancer-pku.cn), HOXA1 expression was found to be upregulated in the lung cancer cohort (Fig. 5A). Gefitinib-resistant analysis demonstrated that KIAA1429 knockdown (sh-KIAA1429) or HOXA1 knockdown (si-HOXA1) reduced the IC_50_ value (inhibitory concentration 50) of PC9-GR cells, and KIAA1429 overexpression or HOXA1 overexpression (HOXA1 OV) rescued the IC_50_ value of PC9-GR cells (Fig. 5B). Wound-healing analysis found that KIAA1429 or HOXA1 knockdown repressed the migrative ability, while HOXA1 or KIAA1429 overexpression recovered the migrative ability repressed by HOXA1 knockdown (Fig. 5C). In vivo xenograft assay showed that the tumor weight and volume were both inhibited upon KIAA1429 knockdown in PC9-GR cells (Fig. 5D, E). In summary, our findings suggested that KIAA1429/HOXA1 axis promoted the proliferation and gefitinib resistance of NSCLC cells.

Discussion

Emerging research has indicated that the dysregulation of epigenetic modifications has played an increasingly important role in human cancers. RNA modification, especially m^6^A modification, is identified to participate in the NSCLC chemotherapy resistance. Present research focuses on the potential regulation of m^6^A methyltransferase KIAA1429 toward the gefitinib resistance of NSCLC.

In spite of the fact that the oncogenic or antigenic modulations of m^6^A key regulators for human cancer have been elaborated, the deepgoing functions on another important layer are still bewildering. Apart from
DNA modification, the m^6A modification that occurred on RNA has been recently proposed regarding epigenetic regulation, including cell differentiation, RNA splicing, and protein translation. In lung cancer, METTL3 expression, as well as m^6A RNA modification, was remarkably increased in TGF-β-induced epithelial−mesenchymal transition of lung cancer cells. METTL3 positively regulates the mRNA stability of JUNB mRNA and m^6A modification enrichment. Moreover, m^6A demethylase ALKBH5 expression was elevated in lung adenocarcinoma, and the m^6A level was upregulated in forkhead box M1 (FOXM1) mRNA. ALKBH5 down-regulates the m^6A modification enrichment of FOXM1 mRNA, thereby increasing FOXM1 expression. Therefore, these findings identify that m^6A regulators could remarkably regulate the tumorigenesis.

Here, we found that m^6A methyltransferase KIAA1429 was upregulated in the gefitinib-resistant NSCLC cells (PC9-GR). Clinically, elevated KIAA1429 expression indicated the unfavorable outcome of NSCLC patients. Thus, this high-expressed KIAA1429 might function as an oncogenic indicator for NSCLC sufferers. In cellular experiments, gain-of-experiments and loss-of-functions were conducted and found that KIAA1429 promoted the migration of PC9-GR. Besides, gefitinib-sensitive assays found that KIAA1429 elevates the IC_{50} value (inhibitory concentration 50) of PC9-GR cells. These findings forcefully prove that KIAA1429 may regulate the gefitinib chemoresistance potential in NSCLC cells.

Apart from the acceleration that KIAA1429 elevates the gefitinib resistance found in present research, more similar findings also evidence the potential function of m^6A in human tumor chemoresistance. In hepatocellular carcinoma (HCC), m^6A methyltransferase is significantly downregulated in sorafenib-resistant HCC cells. METTL3 knockdown promotes sorafenib resistance and angiogenesis gene expression and activates autophagy-associated pathways. METL3 enhances the 3′-untranslated region (3′-UTR) m^6A modification of FOXO3 mRNA to increase its mRNA stability through YTHDF1-dependent manner. In testicular germ cell tumors, METTL3 promotes the m^6A-modified transcription factor-activating enhancer-binding protein 2C (TFAP2C) mRNA to regulate cisplatin treatment. Overall, these data suggest that m^6A modification could remarkably regulate the tumor chemoresistance.
In present research, KIAA1429, which acts as a m6A methyltransferase, could target the 3′-UTR of HOXA1 mRNA. KIAA1429 could regulate the pathogenesis in human pathophysiological process. In oocyte, its growth is accompanied by the accumulation of post-transcriptional regulation and abundant RNAs’ modification. Loss of KIAA1429 leads to abnormal RNA metabolism in oocytes and modulates follicular development24. In gastric cancer, KIAA1429 is upregulated in tissue and cells, and the upregulated KIAA1429 promotes the proliferation by stabilizing c-Jun mRNA via m6A-independent manner25. Therefore, the regulation of KIAA1429 on NSCLC gefitinib resistance makes a great sense.

In summary, the present research found that KIAA1429 was upregulated in the gefitinib-resistant NSCLC cells and indicates the unfavorable outcome. KIAA1429 promotes the gefitinib resistance of NSCLC cells and mechanistically enhances the mRNA stability of HOXA1. Overall, these findings convincingly provide a druggable target for NSCLC patients.

**Materials and methods**

**Clinical specimens**

In total, 30 patients, who underwent surgical resection and were diagnosed as NSCLC, were recruited in the retrospective study between years 2017 and 2018. This research was approved by the Ethics Committee of Cancer Hospital of China Medical University. Written informed consents were obtained from all patients. Tumor tissue and the corresponding fresh tumor tissue samples were obtained from the tissue. Data regarding SCLC clinicopathological features were recorded shown in Table 1.

**Cell lines and culture condition**

Human normal bronchial epithelial cells (NHBE) and NSCLC cell lines (PC9, gefitinib-resistant PC9/GR) were purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). Cell lines were cultured in DMEM (Gibco, Waltham, MA, USA) supplemented with 10% FBS (Gibco), 1% mixture of
penicillin, 25 mmol/L glucose, and streptomycin in a 5% CO₂ incubator at 37 °C.

**Cell transfection**

To overexpress KIAA1429, the full length of KIAA1429 cDNA (gene ID: NM_015496) was amplified and cloned into the lentivirus vector pLenti-copGFP-P2A-Puro-CMV-MCS-3Flag (GeneCopoeia, Madison, WI, USA). Lentivirus vectors containing KIAA1429 shRNA were produced (GenePharma Tech, Shanghai, China). For the transient transfection, siRNA targeting HOXA1 was designed and produced by RiboBio (Guangzhou, China) and transfected with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions.

**Real-time PCR**

Total RNA was isolated from NSCLC tissue and cells using a miRNeasy Mini Kit (Qiagen, Hilden, Germany). The concentration and purity of the extracted RNA were determined using ultraviolet spectrophotometry (Nanodrop ND2000, Thermo Fisher Scientific). In all, 1 μg of total RNA was reverse-transcribed to cDNA using High Capacity RNA cDNA Kit (Applied Biosystems, Carlsbad, CA, USA). The mRNA levels of m⁶A writers (KIAA1429) and target protein (HOXA1) were determined using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI7500 Real-time for real-time PCR analysis with primers (Supplementary Table S1). β-actin acted as the internal control in RT-qPCR assays. Real-time PCR was calculated using 2⁻ΔΔCt method and normalized for relative gene expression.

**Western blotting**

Protein samples were extracted from NSCLC cells using radio-immunoprecipitation assay (RIPA) lysis buffer (Sigma-Aldrich, St Louis, MO, USA) containing protease inhibitor cocktail. The protein concentration was determined by bicinechonic acid (BCA) kit with deionized water. The SDS-PAGE (10%, Beyotime Biotechnology, Shanghai, China) was used for protein separation and the separated protein was transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA). Membranes were blocked and probed with primary antibody (anti-KIAA1429, PA5-95717, Thermo Fisher, 1:1000) and then secondary antibody horseradish peroxidase (HRP)-conjugated anti-β-actin (1:2000, Cell Signaling Technology). Blots were visualized with ECL and quantified using Image Studio software.

**Migrative ability assay**

Wound healing was performed for the migrative ability assay. In brief, cells were seeded in a six-well plate and grew near 90% confluence. Monolayer cells were manually wounded by a 200-ul pipette tip. After being washed by PBS twice, the monolayer was incubated at 37°C fresh medium. At the indicated time, wound closure images were calculated by the following formula: migration rate = migration distance/original distance.

**Gefitinib-sensitive assay**

The drug-sensitivity test of gefitinib was detected using CCK-8 to calculate the half-maximal inhibitory concentration assay (IC₅₀). In brief, PC9-GR cells (1.5 × 10⁴ per well) were cultured in 96-well plates with fresh medium. The corresponding concentration of gefitinib (0.1, 0.5, 1, 5, 10, and 20 μM) was administrated to cells. At the indicated time, Cell Counting Kit-8 (Dojindo, Japan) was performed to measure the drug sensitivity using a microplate reader (Thermo Fisher, USA) at 450 nm.

**m⁶A quantification**

Total RNA was isolated from NSCLC cells using TRIzol (Invitrogen, CA) according to the manufacturer’s instruction. Besides, the quality was analyzed by NanoDrop 3000. The m⁶A quantification in the total RNA was determined using m⁶A RNA methylation quantification kit (ab185912, Abcam). The m⁶A level was colorimetrically quantified according to the absorbance of each well at 450 nm.

### Table 1 Clinopathological feature of NSCLC patients with KIAA1429 expression.

|                | KIAA1429 Low (15) | High (15) | p     |
|----------------|-------------------|-----------|-------|
| Gender         |                   |           |       |
| Male           | 16                | 7         | 9     | 0.498 |
| Female         | 14                | 8         | 6     |
| Age (Year)     |                   |           |       |
| ≥60            | 15                | 6         | 9     | 0.736 |
| <60            | 15                | 9         | 6     |
| TNM            |                   |           |       |
| I−II           | 10                | 6         | 4     | 0.007*|
| III−IV         | 20                | 9         | 11    |
| Differentiation|                   |           |       |
| Well/moderate  | 14                | 7         | 7     | 0.326 |
| Poor           | 16                | 8         | 8     |
| Lymph metastasis|                 |           |       |
| No             | 13                | 5         | 8     | 0.176 |
| Yes            | 17                | 10        | 7     |

*P < 0.05: statistical difference.
RNA immunoprecipitation (RIP) assay

NSCLC cells were lysed with lysis buffer (100 mL) containing protease and ribonuclease inhibitors on ice. Centrifugation was carried out for 5 min at 4 °C. The cell lysate was incubated with protein A/G beads coated with anti-KIAA1429-specific and normal IgG antibody with rotation at 4 °C overnight. The experiment was processed using Magna RIP RNA-Binding Protein Immunoprecipitation kit (Millipore, Billerica, MA, USA) instruction. The interaction between KIAA1429 and HOXA1 was verified by qRT-PCR.

m⁶A–RNA immunoprecipitation assay (MeRIP-qPCR)

MeRIP-qPCR was performed by the methods described previously. In brief, total RNA was isolated from PC9-GR cells treated with gefitinib and then was chemically fragmented into 100–300-nt fragments. The fragments were incubated with m⁶A antibody (ab208577, Abcam, 1:1000) or anti-IgG-conjugated with protein A/G magnetic beads in IP buffer at 4 °C overnight for immunoprecipitation according to the manufacturer’s instruction. Total RNA was eluted with elution buffer and purified. Eluted or input total RNA (10 ng) was re-svers-transcribed using SuperScript First-stand Synthesis system (Invitrogen, US). The enrichment of m⁶A-precipitated mRNA was calculated by quantitative RT-PCR.

RNA stability

The HOXA1 mRNA transcription expression was prevented by the addition of Actinomycin D (2 mg/ml) or negative control (DMSO, Sigma-Aldrich, St. Louis, MO, USA). After treatment, RNA expression was determined by qRT-PCR.

In vivo tumorigenesis

Male BALB/c nude mice (5-week-old) were purchased from Vitalstar Biotechnology Co., Ltd (Beijing, China) to investigate the effects of KIAA1429 on NSCLC tumor growth. This assay was approved by the Ethics Committee of Cancer Hospital of China Medical University. PC9-GR cells stably infected with KIAA1429-targeting shRNA and control were suspended in 100 μL of PBS with Matrigel matrix (BD Biosciences). Then, cells were injected into one of the flanks of BALB/c nude mice. The tumor volumes were measured every 3 days by Vernier caliper and calculated using the formula: (length × width²)/2. After 4 weeks, the mice were sacrificed and the weight was weighed.

Statistical analysis

The patients’ survival curves were analyzed using Kaplan–Meier method with log-rank test. The interaction within clinicopathological features and KIAA1429 expression was analyzed by chi-squared test or Fisher’s test. Intergroup difference was analyzed using Student’s t-test and one-way ANOVA. Statistical analysis was carried out using SPSS software (SPSS, Chicago, IL, USA). P < 0.05 was considered statistically significant.

Author details

1. No. 1 Department of Tuberculosis, Chest Hospital, Shenyang, Liaoning Province 110044, China. 2. Department of Thoracic Surgery, Cancer Hospital of China Medical University, Shenyang, Liaoning Province 110042, China. 3. Department of Thoracic Surgery, Liaoning Cancer Hospital, Shenyang, Liaoning Province 110042, China.

Conflict of interest

The authors declare no competing interests.

References

1. Chen, H., Fu, Q. & Sun, K. Efficacy and prognosis analysis of surgical treatment for bilateral synchronous multiple primary non-small cell lung cancer. Rev. da Associaçao Med. Brasileira 24, 2245–2252 (1992).
2. Jiang, S. S. et al. Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review. BMC Pulm. Med. 19, 262 (2019).
3. Ma, X., Liang, A. L. & Liu, Y. J. Research progress on the relationship between lung cancer drug-resistance and microRNAs. J. Cancer 10, 6865–6875 (2019).
4. Nishino, M., Soejima, K. & Mitsudomi, T. Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res. 8, 5298–5307 (2019).
5. Iwahori, K. et al. Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma case report. Neurochirurgie 66, 477–483 (2020).
6. Roeppe, J., Kurz, S., Groh, C. & Griesinger, F. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncol. 17, 471–486 (2020).
7. Leonetti, AM, Chu, MT, Ramnaraign, FO, Holm, S. & Walters, BJ. An emerging role of m6A in memory: a case for translational priming. Int. J. Mol. Sci. 21, 7447 (2020).
8. Ma, Z., Gao, X., Shuai, Y., Xing, X. & Ji, J. The m6A epitranscriptome opens a new charter in immune system logic. Epigenetics 9, 1–19 (2020).
9. Dai, F. et al. Crosstalk between RNA m6A modification and non-coding RNA contributes to cancer growth and progression. Mol. Ther. Nucleic Acids 22, 62–71 (2020).
10. Zhao, W. et al. Epigenetic regulation of m6A modifications in human cancer. Mol. Ther. Nucleic Acids 19, 405–412 (2020).
11. Li, D. et al. LncRNA MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Mol. Ther. Nucleic Acids 19, 109–123 (2020).
12. Han, Q. et al. KIAA1429 promotes osteosarcoma progression by promoting stem cell properties and is regulated by miR-143-3p. Cell Cycle 19, 1172–1185 (2020).
13. Yi, L., Wu, G., Guo, L., Zou, X. & Huang, P. Comprehensive analysis of the PD-L1 and immune infiltrates of miR6A RNA methylation regulators in head and neck squamous cell carcinoma. Mol. Ther. Nucleic Acids 21, 299–314 (2020).
14. Zhong, L. et al. METTL3 induces AAA development and progression by modulating N6-methyladenosine-dependent primary miR34a processing. Mol. Ther. Nucleic Acids 21, 394–411 (2020).
15. Xu, Z. et al. N6-methyladenosine RNA modification in cancer therapeutic resistance: current status and perspectives. Biochem. Pharmacol. 182, 114258 (2020).
16. Zhang, Y. et al. m6A modification in RNA: biogenesis, functions, and roles in gliomas. J. Exp. Clin. Cancer Res. 39, 192 (2020).
17. Longenecker, J. Z., Gilbert, C. J., Golubeva, V. A., Martens, C. R. & Accornero, F. Epitranscriptomics in the heart: a focus on m6A. Curr. Heart Fail. Rep. 17, 205–212 (2020).
18. Ying, Y. et al. Novel insights into the interplay between m6A modification and non-coding RNAs in cancer. J. Cell. Mol. Med. 19, 121 (2020).
19. Hu, X. et al. IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader. Cell Death Differ. 27, 1782–1794 (2020).
20. Wanna-Udom, S. et al. The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem. Biophys. Res. Commun. 524, 150–155 (2020).
21. Chao, Y., Shang, J. & Ji, W. ALKBHS-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia. Biochem. Biophys. Res. Commun. 521, 499–506 (2020).
22. Lin, Z. et al. RNA m(6)A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 39, e103181 (2020).
23. Wei, J. et al. METTL3 potentiates resistance to cisplatin through m6A modification of TFAP2C in seminoma. J. Cell. Mol. Med. 24, 11366–11380 (2020).
24. Hu, Y. et al. Oocyte competence is maintained by m(6)A methyltransferase KIAA1429-mediated RNA metabolism during mouse follicular development. Cell Death Differ. 27, 2468–2483 (2020).
25. Miao, R., Dai, C. C., Mei, L., Xu, J., Sun, S. W. & Xing, Y. L. et al. KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J. Cell. Physiol. 235, 7420–7432 (2020).